E(1F&k2G(1F&l1H&n11WdLetterhead&l7C&a200CType=M1A##;npat=9377406;pfx=Mme ;pnom=NLEND               ;prn=URSULE              ;cmed=LEGAL1;numdos=140120661 ;gmed=    ;
&a200Cnommed=.Dr LE GUINER Alexandra                 ;adm1=10 bd de la Libert{-remp.du Dr Hazan    ;
&a200Cadm2=BP10025 -93260 LES LILAS                ;adm3=                                        ;datedos=20/01/14;
&a200Cccor=        ;nomcor=                                        ;
&a-4R(s0p10h12v0s0b3T(1F                                                                    (s0p16h8.v0s0b3T(1F p1/2  (s0p10h12v0s0b3T(1F 






&a12R
                                            .Dr LE GUINER Alexandra                 
                                            10 bd de la Libert{-remp.du Dr Hazan    
                                            BP10025 -93260 LES LILAS                
  Mme  NLEND URSULE                                                       
  NJF:NLEND               DN:22/12/88
  36 AVENUE DU DR GLEY                     
  75020 PARIS                                    LES LILAS, le 20/01/14 @ 17H40
  Dossier N[ 140120661 du(s0p10h12v0s3b3T(1F 20/01/14                                        (s0p10h12v0s0b3T(1F 


    (s1p16v0s4101T(1F                                   H E M A T O L O G I E           (s0p10h12v0s0b3T(1F
   (s0p16h8.v0s0b3T(1F                                               (Beckman Coulter HMX)                    (s0p10h12v0s0b3T(1F
                                                         (s0p16h8.v0s0b3T(1F  R{f{rence           Ant{rieurs        (s0p10h12v0s0b3T(1F
   NUMERATION GLOBULAIRE

     Leucocytes . . . . . . . . .      6.300 /mm3      (s0p16h8.v0s0b3T(1F 4.000 @ 10.000  (s0p10h12v0s0b3T(1F
     H{maties . . . . . . . . . .  4.370.000 /mm3      (s0p16h8.v0s0b3T(1F4000000 @ 5200000 (s0p10h12v0s0b3T(1F
     H{moglobine. . . . . . . . .   *    9,2 g%        (s0p16h8.v0s0b3T(1F   12,0 @ 15,0    (s0p10h12v0s0b3T(1F
     H{matocrite. . . . . . . . .   *   30,7 %         (s0p16h8.v0s0b3T(1F   37,0 @ 47,0    (s0p10h12v0s0b3T(1F
     V.G.M. . . . . . . . . . . .   *     70 u3        (s0p16h8.v0s0b3T(1F     80 @ 97      (s0p10h12v0s0b3T(1F
     C.C.M.H. . . . . . . . . . .   *   30,0 %         (s0p16h8.v0s0b3T(1F   31,0 @ 36,0    (s0p10h12v0s0b3T(1F
     T.C.M.H. . . . . . . . . . .   *   21,1 uug       (s0p16h8.v0s0b3T(1F   27,0 @ 32,0    (s0p10h12v0s0b3T(1F

   (s0p10h12v0s3b3T(1FFORMULE SANGUINE                                                            (s0p10h12v0s0b3T(1F

     Polynucl{aires neutrophiles.   66,3 %   4177/mm3  (s0p16h8.v0s0b3T(1F                  (s0p10h12v0s0b3T(1F
     Polynucl{aires {osinophiles.    1,2 %     76/mm3  (s0p16h8.v0s0b3T(1F                  (s0p10h12v0s0b3T(1F
     Polynucl{aires basophiles. .    0,2 %     13/mm3  (s0p16h8.v0s0b3T(1F                  (s0p10h12v0s0b3T(1F
     Lymphocytes. . . . . . . . .   23,8 %   1499/mm3  (s0p16h8.v0s0b3T(1F                  (s0p10h12v0s0b3T(1F
     Monocytes. . . . . . . . . .    8,5 %    536/mm3  (s0p16h8.v0s0b3T(1F                  (s0p10h12v0s0b3T(1F
 -



   NUMERATION DES PLAQUETTES. . .   *  401.000 /mm3      (s0p16h8.v0s0b3T(1F150.000 @ 400.000 (s0p10h12v0s0b3T(1F

     V.M.P.(Volume plaquettaire).        6,4 u3        (s0p16h8.v0s0b3T(1F                  (s0p10h12v0s0b3T(1F

















(s0p16h8.v0s0b3T(1F (s0p10h12v0s0b3T(1F     
                                                        &a69R&a58C(s0p16h8.v0s0b3T(1F r{sultatsRECTOVERSO(s0p10h12v0s0b3T(1F 
&a71R&a10C(s0p16h8.v0s0b3T(1F C.BOADAS(s0p10h12v0s0b3T(1F &a71R&a33.5C(s0p16h8.v0s0b3T(1F Biologiste M{dical(s0p10h12v0s0b3T(1F &a71R&a61C(s0p16h8.v0s0b3T(1F S.JOURNO(s0p10h12v0s0b3T(1F 
(s0p16h8.v0s0b3T(1F Dossier n[ 140120661  du 20/01/14 Mme  NLEND URSULE                        n{(e) le :: 22/12/88(s0p10h12v0s0b3T(1F 


    (s1p16v0s4101T(1F                                           B I O C H I M I E       (s0p10h12v0s0b3T(1F
   (s0p16h8.v0s0b3T(1F                              (Analyseur VITROS 250 -ORTHO-CLINICAL DIAGNOSTICS)        (s0p10h12v0s0b3T(1F
                                                         (s0p16h8.v0s0b3T(1F  R{f{rence           Ant{rieurs        (s0p10h12v0s0b3T(1F

   CREATININE . . . . . . . . . .        7,0 mg/l      (s0p16h8.v0s0b3T(1F    6,0 @ 10,0    (s0p10h12v0s0b3T(1F
                                       61,95 umol/l    (s0p16h8.v0s0b3T(1F  53,10 @ 88,50   (s0p10h12v0s0b3T(1F
    (s0p16h8.v0s0b3T(1FTechnique enzymatique r{actifs ORTHO calibr{s/meth.de r{f.IDMS sur VITROS350 (s0p10h12v0s0b3T(1F
   Clairance cr{atinine MDRD          101,96 ml/mn

   GLYCEMIE . . . . . . . . . . .       0,88 g/l       (s0p16h8.v0s0b3T(1F                  (s0p10h12v0s0b3T(1F
                                        4,88 mmol/l    (s0p16h8.v0s0b3T(1F                  (s0p10h12v0s0b3T(1F

   Heure du pr{l}vement . . . . . . . . . 15h30

   (s0p10h12v0s3b3T(1FEXPLORATION D'UNE ANOMALIE LIPIDIQUE                                        (s0p10h12v0s0b3T(1F
   (s0p16h8.v0s0b3T(1FLDL-C calcul{ par la formule de FRIEDEWALD pour des triglyc{rides < 3,4 g/l             (s0p10h12v0s0b3T(1F

   CHOLESTEROL TOTAL. . . . . . .       1,57 g/l       (s0p16h8.v0s0b3T(1F   1,30 @ 2,00    (s0p10h12v0s0b3T(1F
                                        4,05 mmol/l    (s0p16h8.v0s0b3T(1F   3,35 @ 5,16    (s0p10h12v0s0b3T(1F
    (s0p16h8.v0s0b3T(1FTechnique enzymatique r{actifs ORTHO sur Vitros350 (s0p10h12v0s0b3T(1F

   Cholesterol H.D.L. . . . . . .       0,93 g/l       (s0p16h8.v0s0b3T(1F   sup. @ 0,45    (s0p10h12v0s0b3T(1F
   (s0p16h8.v0s0b3T(1F(Technique HDL direct Vitros) (s0p10h12v0s0b3T(1F

   Cholesterol L.D.L. . . . . . .       0,50 g/l       (s0p16h8.v0s0b3T(1F   inf. @ 1,60    (s0p10h12v0s0b3T(1F

   Rapport Cholest{rol / H.D.L. .       1,69           (s0p16h8.v0s0b3T(1F                  (s0p10h12v0s0b3T(1F


   TRIGLYCERIDES. . . . . . . . .       0,69 g/l       (s0p16h8.v0s0b3T(1F   0,35 @ 1,35    (s0p10h12v0s0b3T(1F
                                        0,79 mmol/l    (s0p16h8.v0s0b3T(1F   0,40 @ 1,54    (s0p10h12v0s0b3T(1F

   ASPECT DU SERUM. . . . . . . .    Limpide           (s0p16h8.v0s0b3T(1F                  (s0p10h12v0s0b3T(1F


   (s0p10h12v0s3b3T(1FInterpr{tation                                                              (s0p10h12v0s0b3T(1F
   (s0p16h8.v0s0b3T(1F   FACTEURS DE RISQUE biologiques:                                                      (s0p10h12v0s0b3T(1F
   (s0p16h8.v0s0b3T(1F   -Cholesterol HDL:Homme <0,35 g/l Femme <0,45 g/l  -Lp(a): >0,30 g/l                  (s0p10h12v0s0b3T(1F
   (s0p16h8.v0s0b3T(1F   OBJECTIFS THERAPEUTIQUES:                                                            (s0p10h12v0s0b3T(1F
   (s0p16h8.v0s0b3T(1F   -Pr{vention primaire et moins de 2 facteurs de risque*                               (s0p10h12v0s0b3T(1F
   (s0p16h8.v0s0b3T(1F       Cholest{rol total < 2,00 g/l et cholest{rol LDL < 1,60 g/l                       (s0p10h12v0s0b3T(1F
   (s0p16h8.v0s0b3T(1F   -Pr{vention primaire + 2 facteurs de risque* ou secondaire                           (s0p10h12v0s0b3T(1F
   (s0p16h8.v0s0b3T(1F       Cholesterol total < 2,00 g/l et cholesterol LDL < 1,30 g/l                       (s0p10h12v0s0b3T(1F
   (s0p16h8.v0s0b3T(1F   -Ath{roscl{rose patente                                                              (s0p10h12v0s0b3T(1F
   (s0p16h8.v0s0b3T(1F       Cholest{rol total < 1,50 g/l et cholest{rol LDL < 1,00 g/l                       (s0p10h12v0s0b3T(1F
   (s0p16h8.v0s0b3T(1F   *Tabagisme,diab}te,HTA,ob{sit{ s{v}re,ant{c{dents familiaux,age..                    (s0p10h12v0s0b3T(1F

   (s0p10h12v0s3b3T(1F        - EXAMENS  TRANSMIS -                                               (s0p10h12v0s0b3T(1F

   (s0p16h8.v0s0b3T(1FExamen transmis au Laboratoire BIOMNIS (anct. LCL)                                      (s0p10h12v0s0b3T(1F
   (s0p16h8.v0s0b3T(1F( 78 av.de Verdun BP 110 94208 IVRY/SEINE C{dex T{l : 01.49.59.16.16)                   (s0p10h12v0s0b3T(1F
   (s0p16h8.v0s0b3T(1FExamen transmis au Laboratoire BIOMNIS (anct. LCL)                                      (s0p10h12v0s0b3T(1F
   (s0p16h8.v0s0b3T(1F( 78 av.de Verdun BP 110 94208 IVRY/SEINE C{dex T{l : 01.49.59.16.16)                   (s0p10h12v0s0b3T(1F
   SEROLOGIE DE LA COQUELUCHE
 -
   CRP ULTRA SENSIBLE

(s0p16h8.v0s0b3T(1F (s0p10h12v0s0b3T(1F 
(s0p16h8.v0s0b3T(1F  / (s0p10h12v0s0b3T(1F &a69R&a58C(s0p16h8.v0s0b3T(1F r{sultats RECTOVERSO(s0p10h12v0s0b3T(1F 
&a71R&a10C(s0p16h8.v0s0b3T(1F C.BOADAS(s0p10h12v0s0b3T(1F &a71R&a33.5C(s0p16h8.v0s0b3T(1F Biologiste M{dical(s0p10h12v0s0b3T(1F &a71R&a61C(s0p16h8.v0s0b3T(1F S.JOURNO(s0p10h12v0s0b3T(1F               &a200Cff##